Antibiotic resistance lasts up to a year

May 18, 2010

Patients prescribed antibiotics in primary care may develop a resistance that lasts up to 12 months, according to research published in the British Medical Journal today.

It is widely recognised that resistance to is a major threat to public health. However, according to the researchers, this is not seen by most clinicians or patients as a reason to refrain from using them, with many regarding the problem as minimal.

To address a lack of systematic reviews in the area, the authors analysed 24 existing studies of resistance in individual patients prescribed antibiotics in primary care, mainly for respiratory or urinary infections.

They found strong evidence that individuals prescribed an antibiotic in for a respiratory or urinary infection develop a resistance. The effect is greatest in the month immediately after treatment, but may last for up to a year, and this residual effect may be a driver for high levels of resistance in the community.

The review provides the evidence needed to quantify the link between individual prescribing decisions and the problem of resistance, the authors conclude. They say it highlights that the only way to avoid the "vicious cycle of resistance" is to avoid the initial use of antibiotics wherever possible. However, they also call for more clinical trials to strengthen the evidence base.

In an accompanying analysis, two specialists in economics and health policy argue that new antibiotics to tackle multi-drug resistant bacteria are much needed. They show how financial incentives might be used to persuade drug companies to develop new antibiotics, and suggest that such action needs to be accompanied by efforts to tackle overuse of antibiotics, which is currently fuelling the spread of resistant bacteria.

These views are reiterated in an editorial by three international experts who call for economic strategies to bring to market, and to conserve existing antibacterials. "Nothing less than the future of medicine, from organ transplants to chemotherapy, is at stake, and there will be no second chances," they conclude.

Explore further: US scientists make embryonic stem cells from adult skin

add to favorites email to friend print save as pdf

Related Stories

Resistant gut bacteria will not go away by themselves

Jun 19, 2007

E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, ...

Antibiotics-resistant gulls worry scientists

Jun 18, 2009

The resistance pattern for antibiotics in gulls is the same as in humans, and a new study by Uppsala University researchers shows that nearly half of Mediterranean gulls in southern France have some form of resistance to ...

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments : 0

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.